Show simple item record

dc.contributor.authorHansen, F
dc.contributor.authorJarvis, Michael A
dc.contributor.authorFeldmann, H
dc.contributor.authorRosenke, K
dc.date.accessioned2021-08-09T12:36:53Z
dc.date.issued2021-04-07
dc.identifier.issn2076-2607
dc.identifier.issn2076-2607
dc.identifier.otherARTN 772
dc.identifier.urihttp://hdl.handle.net/10026.1/17497
dc.description.abstract

<jats:p>Lassa fever causes an approximate 5000 to 10,000 deaths annually in West Africa and cases have been imported into Europe and the Americas, challenging public health. Although Lassa virus was first described over 5 decades ago in 1969, no treatments or vaccines have been approved to treat or prevent infection. In this review, we discuss current therapeutics in the development pipeline for the treatment of Lassa fever, focusing on those that have been evaluated in humans or animal models. Several treatments, including the antiviral favipiravir and a human monoclonal antibody cocktail, have shown efficacy in preclinical rodent and non-human primate animal models and have potential for use in clinical settings. Movement of the promising preclinical treatment options for Lassa fever into clinical trials is critical to continue addressing this neglected tropical disease.</jats:p>

dc.format.extent772-772
dc.format.mediumElectronic
dc.languageen
dc.language.isoen
dc.publisherMDPI AG
dc.subjectLassa
dc.subjectLASV
dc.subjectantiviral
dc.subjecttherapeutic
dc.subjectantibody
dc.subjectanimal model
dc.titleLassa Virus Treatment Options
dc.typejournal-article
dc.typeJournal Article
dc.typeReview
plymouth.author-urlhttps://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000643291800001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008
plymouth.issue4
plymouth.volume9
plymouth.publication-statusPublished online
plymouth.journalMicroorganisms
dc.identifier.doi10.3390/microorganisms9040772
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/School of Biomedical Sciences
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
dc.publisher.placeSwitzerland
dcterms.dateAccepted2021-04-03
dc.rights.embargodate2021-8-13
dc.identifier.eissn2076-2607
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.3390/microorganisms9040772
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-04-07
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV